What happened with CLDX today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Celldex Therapeutics is advancing drug candidates such as barzolvolimab through clinical development. It has not submitted a marketing application and cannot sell a candidate in the United States without FDA approval. If approved, it could sell medicines itself or work with commercial partners; future revenue would depend on physicians and patients adopting the drugs and insurers and other payors covering them.
For now, Celldex relies on its cash and investments to fund development and says it needs additional financing. Historically, operating funding has also come from collaboration partners, government entities, and contract manufacturing and research services. It outsources much of its clinical development and large-scale manufacturing, with no qualified backup for some manufacturers. Continuing development therefore depends on funding and these contractors as well as successful trials.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Celldex's prospects hinge on barzolvolimab succeeding in clinical trials and standing apart from competing mast-cell therapies, including Blueprint Medicines' small-molecule KIT inhibitor program.
Jasper Therapeutics, Inc.'s briquilimab is a direct rival to Celldex's barzolvolimab: both are antibodies targeting KIT for mast-cell diseases. Jasper's trial results in chronic spontaneous and inducible urticaria offer a close comparison for barzolvolimab.
Novartis's Xolair and remibrutinib set efficacy and commercial benchmarks for Celldex's barzolvolimab in chronic urticaria. For this prescription-medicine seller, watch those drugs' results in urticaria rather than its overall sales.
Sanofi challenges Celldex's barzolvolimab through Dupixent in chronic spontaneous urticaria and inflammatory skin diseases, and through drugs targeting KIT. Watch its early Phase 1 oral KIT programs for progress in a different approach to the same target.
Regeneron's Dupixent, co-developed with Sanofi, competes for the patients Celldex seeks with barzolvolimab. Dupixent's results in chronic spontaneous urticaria, prurigo nodularis and atopic dermatitis are the relevant comparison, rather than Regeneron's eye-drug sales.
Evommune, Inc.'s EVO756 competes with Celldex's barzolvolimab for chronic spontaneous urticaria patients who do not respond to antihistamines, by blocking MRGPRX2 on mast cells. Its Phase 2b trial measures the change in urticaria activity after 12 weeks, a concrete test of this alternative approach.
Enanta Pharmaceuticals, Inc.'s oral KIT inhibitor EP262 offers a competing treatment approach in chronic spontaneous urticaria to Celldex's injectable KIT antibody barzolvolimab.
Incyte's povorcitinib competes with Celldex's effort to expand barzolvolimab into prurigo nodularis. Progress in that program, rather than Incyte's JAKAFI sales, is what bears on this opportunity for Celldex.
Amgen's rocatinlimab program competes with Celldex's barzolvolimab opportunity in atopic dermatitis and prurigo nodularis. Amgen sells medicines to wholesalers and healthcare providers; rocatinlimab's clinical results in those two diseases are the more direct signal for Celldex.
Regeneron Pharmaceuticals Inc earningsREGN
If Regeneron’s report updates Dupixent in urticaria, prurigo nodularis or atopic dermatitis, it will show the competitive pressure facing Celldex across these treatment opportunities.
Focus on Dupixent’s results in chronic spontaneous urticaria, prurigo nodularis and atopic dermatitis—not Regeneron’s total sales or eye-drug sales. Positive results in these diseases would show an established therapy competing more strongly for the patient groups Celldex seeks; weaker results would offer less evidence of that pressure, not proof that Celldex’s candidates work.
Celldex Therapeutics, Inc earningsThis company
Celldex’s report will show how its clinical-development spending and cash use compare with the service revenue that helps fund them.
Read operating cash used alongside contract-service revenue from Rockefeller University. Higher cash use as that revenue declines would mean development relies more on existing cash or new financing and partnerships; contained cash use would show Celldex is limiting its funding needs despite the revenue decline.
